GOLDMAN SACHS GROUP INC

Major Shareholding Notification • Jan 14, 2026

National Storage Mechanism | Additional information

RNS Number : 9265O

Goldman Sachs Asset Management LP

14 January 2026

The 'Form 8.1b-Avadel Pharmaceuticals plc' announcement released on 14/01/2026 at 07:26 under RNS No '85220' was released in error and should be disregarded.

FORM 8.1(b)(ii)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(b)(ii) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT FUND MANAGERS ON BEHALF OF DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of exempt fund manager	(GS) GOLDMAN SACHS ASSET MANAGEMENT, L.P.
Company dealt in	AVADEL PHARMACEUTICALS PLC
Class of relevant security to which the dealings being disclosed relate (Note1)	USD 0.01 ordinary shares
Date of dealing	12 January 2026

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	180,688	(0.18)	0	(0.00)
(2) Derivatives (other than options)	0	(0.00)	0	(0.00)
(3) Options and agreements to purchase/sell	0	(0.00)	0	(0.00)
Total	180,688	(0.18)	0	(0.00)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3.    DEALINGS (Note 3)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit  (Note 4)
Sale	20	21.5000 USD

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction  (Note 5)	Number of relevant securities  (Note 6)	Price per unit  (Note 4)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,e.g. call option	Writing, selling,  purchasing, varying etc.	Number of securities to which the option relates  (Note 6)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit  (Note 4)

(ii)            Exercising

Product name,e.g. call option	Number of securities	Exercise price per unit  (Note 4)

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

Nature of transaction  (Note 6)	Details	Price per unit (if applicable)  (Note 4)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated.
NONE

Is a Supplemental Form 8 attached? (Note 9)        NO

Date of disclosure	14 January 2026
Contact name	Papa Lette and Andrzej Szyszka
Telephone number	+33(1) 4212 1459 / +48(22) 317 4817
Name of offeree/offeror with which connected	AVADEL PHARMACEUTICALS PLC
Nature of connection (Note 9)	Advisor to Offeree

Notes

1. See the definition of relevant securities in Rule 2.1 of Part A of the Rules.

2. See the definition of interest in a relevant security in Rule 2.6 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.

If an option over new securities is acquired or exercised, the relevant interest should be disclosed under (1) Relevant securities If an option over existing relevant securities is acquired or exercised, the relevant interest should be disclosed under (3) Options and agreements to purchase/sell.

3. See the definition of a dealing in Rule 2.1 of Part A of the Rules.

4. For all prices and other monetary amounts, the currency must be stated.

5. If a long position has been increased or decreased as a result of the dealing, write an increased long or a decreased long respectively. If a short position has been increased or decreased as a result of the dealing, write an increased short or a decreased short respectively. If the dealing has not resulted in a long or short position being increased or reduced, give details of the variation or other dealing.

6. See Rule 2.6(d) of Part A of the Rules.

7. State type of dealing, e.g. subscription, conversion, exercise etc.

8. Where there are open option positions or open derivative positions (other than CFDs), or where there is an agreement to purchase or to sell, Supplemental Form 8 must be completed.

9. See the definition of a connected fund manager in Rule 2.2 of Part A of the Rules.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to the Rules are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2013

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPEALFLFFSKEFA